# Mirador Therapeutics funding rounds and investors

As of 14 Oct 2026, Mirador Therapeutics has raised $250M across 1 verified round on record; latest: $250 million Series B, announced 12 Jan 2026.

Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases.

Website: https://miradortx.com  
Headquarters: San Diego, CA  
Page: https://fireround.dev/companies/miradortx.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-01-12 | Series B | $250 million | not stated | Adage Capital Management, Arch Venture Partners, Blue Owl Healthcare Opportunities, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Fund, Moore Strategic Ventures, OrbiMed, Point72, TCGX, T. Rowe Price, Venrock Healthcare Capital Partners, Woodline Partners | [businesswire.com](https://www.businesswire.com/news/home/20260112649752/en/Mirador-Accelerates-Multi-Asset-Clinical-Pipeline-in-Immuno-Fibrotic-Disease-Closes-%24250-Million-Series-B-with-Premier-Investors) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.